Patient characteristics (immunotherapy cohort)
| . | All patients (N = 45) . | Patients with TP53 mutations and/or 17p abnormalities (n = 15*) . |
|---|---|---|
| Age, median (range), y | 61 (27-81) | 61 (27-81) |
| Males/females, n | 24/21 | 8/7 |
| AML risk stratification (2017 ELN), n (%) | ||
| Favorable | 3 (6.7) | 0 (0) |
| Intermediate | 8 (17.8) | 0 (0) |
| Adverse | 34 (75.6) | 15 (100) |
| Secondary AML, n (%) | 15 (33.3) | 7 (46.7) |
| No. of prior lines of therapy, median (range) | 2 (1-9) | 2 (1-4) |
| . | All patients (N = 45) . | Patients with TP53 mutations and/or 17p abnormalities (n = 15*) . |
|---|---|---|
| Age, median (range), y | 61 (27-81) | 61 (27-81) |
| Males/females, n | 24/21 | 8/7 |
| AML risk stratification (2017 ELN), n (%) | ||
| Favorable | 3 (6.7) | 0 (0) |
| Intermediate | 8 (17.8) | 0 (0) |
| Adverse | 34 (75.6) | 15 (100) |
| Secondary AML, n (%) | 15 (33.3) | 7 (46.7) |
| No. of prior lines of therapy, median (range) | 2 (1-9) | 2 (1-4) |
BM samples from 13 out of 15 patients were available for immune gene expression profiling. All 15 patients with TP53 mutations/17p abnormalities were included in clinical analyses.